Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.30 -2.45%

-$0.27 today

Market cap
$430.84M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.67M

Average 1.21M

PHAT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 79.4%

Gross margin was 79.4% in Q1 FY2026, down 7.5 pp from a year earlier. On a trailing-twelve-month basis it was 84.9%, down 1.3 pp year over year.

Context

  • Gross margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
79.4%-7.3 pp QoQ
Last fiscal yearDec 2025
87.1%+1.5 pp YoY
LTMMar 2026
84.9%-1.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.5 pp——
1 year+1.5 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
87.1%
Year-over-year change
+1.5pp

Gross Margin vs competitors

How PHAT compares with its peers on the latest reported figures

  • PHAT's LTM Mar 2026 gross margin of 84.9% is the lowest of the 2 companies compared; the peer median is 91.9%.
  • Its year-over-year change of -1.3 pp is the lowest of 2, against a peer median of +7.7 pp.
PHAT Competitors Peer median
Gross Margin for PHAT and competitors
Company Period LTM level YoY 3-year change
ARDXArdelyx, Inc.LTM Mar 202691.9% +7.7 pp-2.6 pp
PHATPhathom Pharmaceuticals, Inc.LTM Mar 202684.9% -1.3 pp—
Peer median (excluding PHAT) 91.9%+7.7 pp-2.6 pp

Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00682K55.25M175.11M
Cost of Revenue521K620K167K7.97M22.6M
Gross Profit(521K)(620K)515K47.28M152.51M
Gross Margin——75.5%85.6%87.1%
Research & Development72.34M71.44M49.9M34.08M32.78M
Selling, General & Admin62.22M100.38M117.93M290.66M279.72M
Operating Expenses134.56M171.82M167.83M324.75M312.5M
Depreciation & Amortization521K620K575K795K633K
EBITDA(136.57M)(169.8M)(159.05M)(261.52M)(152.5M)
EBITDA Margin——-23321.0%-473.3%-87.1%
Operating Income(135.08M)(172.44M)(167.31M)(277.47M)(159.99M)
Operating Margin——-24532.6%-502.2%-91.4%
Interest Income41K2.13M7.88M15.16M7.04M
Interest Expense6.79M27.31M41.97M72.01M68.12M
Other Income / Expenses(8.8M)(25.28M)(34.28M)(56.86M)(61.26M)
Income Before Tax(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Pre-Tax Margin——-29558.9%-605.1%-126.3%
Income Tax Expense00000
Net Income(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Net Margin——-29558.9%-605.1%-126.3%
EPS (Basic)(4.00)(5.70)(3.93)(5.29)(3.03)
EPS (Diluted)(4.00)(5.70)(3.93)(5.29)(3.03)
Weighted Avg Shares37M39.12M51.29M63.18M72.92M
Weighted Avg Shares (Diluted)37M39.12M51.29M63.18M72.92M

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Intrinsic Alpha fair value

Locked

Current Price

$5.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.